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Abstract
Background: Anti-mitotic compounds (microtubule de-stabilizers) such as vincristine and vinblastine have been shown
clinically successful in treating various cancers. However, development of drug-resistance cells limits their efficacies in
clinical situations. Therefore, experiments were performed to determine possible drug resistance mechanisms related to the
application of anti-mitotic cancer therapy.
Principal Findings: A KB-derived microtubule de-stabilizer-resistant KB-L30 cancer cell line was generated for this study. KB-
L30 cells showed cross-resistance to various microtubule de-stabilizers including BPR0L075, vincristine and colchicine
through multiple-drug resistant (MDR)-independent mechanisms. Surprisingly, KB-L30 cells showed hyper-sensitivity to the
microtubule-stabilizer, paclitaxel. Results of the RT-PCR analysis revealed that expression of both class II and III b-tubulin was
down-regulated in KB-L30 cells as compared to its parental KB cancer cells. In addition, DNA sequencing analysis revealed six
novel mutation sites present in exon four of the bI-tubulin gene. Computational modeling indicated that a direct
relationship exists between bI-tubulin mutations and alteration in the microtubule assembly and dynamic instability in KB-
L30 cells and this predicted model was supported by an increased microtubule assembly and reduced microtubule dynamic
instability in KB-L30 cells, as shown by Western blot analysis.
Conclusions and Significance: Our study demonstrated that these novel mutations in exon four of the bI-tubulin
induced resistance to microtubule de-stabilizers and hyper-sensitivity to microtubule stabilizer through an
alteration in the microtubule assembly and dynamics in cancer cells. Importantly, the current study reveals that
cancer cells may acquire drug resistance ability to anti-mitotic compounds through multiple changes in the
microtubule networks. This study further provided molecular information in drug selection for patients with specific
tubulin mutations.
Citation: Cheung CHA, Wu S-Y, Lee T-R, Chang C-Y, Wu J-S, et al. (2010) Cancer Cells Acquire Mitotic Drug Resistance Properties Through Beta I-Tubulin
Mutations and Alterations in the Expression of Beta-Tubulin Isotypes. PLoS ONE 5(9): e12564. doi:10.1371/journal.pone.0012564
Editor: Wen-Liang Zhou, Sun Yat-Sen University, China
Received June 21, 2010; Accepted August 12, 2010; Published September 3, 2010
Copyright:  2010 Cheung et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by intramural grants NSC98-3114-M-006-002 and NSC98-2323-B-400-004 from the National Science Council, Taiwan, Republic
of China, DOH99-TD-C-111-004 from the Department of Health, Taiwan, Republic of China and CA-097-PP-02 from the National Health Research Institutes, Taiwan,
Republic of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jychang@nhri.org.tw
Introduction
Microtubules are protein filaments of the cytoskeleton
composed of a-tubulin and b-tubulin molecules. In cells,
microtubule filaments rapidly alternate between phases of
growth and shrinkage (dynamic instability) during cell cycle
[1]. Since microtubules play crucial roles in the regulation of the
mitotic apparatus, disruption of microtubules can induce cell
cycle arrest in M phase, the formation of abnormal mitotic
spindles, and finally triggering of signals for apoptosis. The
discovery that the cytotoxic activity of various compounds is
through the interference with the mitotic spindle apparatus has
attracted much attention within the past two decades, and
m i c r o t u b u l e sh a v eb e c o m ea na t t r a ctive pharmacological target
for anticancer drug discovery. Anti-mitotic compounds such as
vincristine, vinblastine (microtubule-destabilizing Vinca alkaloid)
and paclitaxel (microtubule-stabilizing taxane) have been
developed to target cancers clinically [2,3]. Although the
taxanes and Vinca alkaloids are effective for the management
of different malignancies, their potential is limited by the
development of multidrug resistance (MDR) [4,5]. MDR is
multi-factorial, with one pathway leading to resistance mediated
by the over-expression of transmembrane efflux pumps, namely,
the Mr 170,000 P-glycoprotein (P-gp170/MDR) and the
multidrug resistance protein (MRP) [5,6]. Besides the expression
of MDR, additional mechanisms of resistance to anti-mitotic
drugs have also been described previously. These include
changes in tubulin isotype expression and mutations in the
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12564tubulin gene [7,8]. Cells containing mutations such as D45Y,
S172A, D197N, D224N, S234N, L240I and K350N in the class
I beta-tubulin have been found resistant to colchicine and Vinca
alkaloid [7]. On the other hand, cells containing mutations such
as P173A, Q292E and Y422C in the class I beta-tubulin have
been found resistant to epothilone (microtubule stabilizing
agent) [9]. Interestingly, over-expression of bIII-tubulin has
been shown in paclitaxel-resistant cells [10,11,12]. However,
combined changes (alternations in in tubulin isotype expression
and mutations in the b-tubulin gene) in the microtubule
networks are seldom demonstrated in the anti-mitotic drug
resistance cancer cells.
In this study, a microtubule de-stabilizer-resistant cancer cell
line was used to investigate novel changes present in cells that
were able to induce resistance to anti-mitotic compounds. KB-
L30 is a KB-derived BPR0L075 (microtubule de-stabilizer)-
resistant cancer cell line. Our published study revealed that KB-
L30 cells over-expressed survivin, leading to the stabilization of
microtubule networks and resulting in resistance to microtubule
de-stabilizing compounds [13]. However, down-regulation of
survivin only partially restored the drug-sensitivity to microtubule
de-stabilizers colchicine and BPR0L075, suggesting that addi-
tional drug-resistant mechanism is present in this cell line [13].
Here, we investigated additional mechanisms that may be
responsible for drug-resistance to microtubule de-stabilizers in
KB-L30 cells.
Figure 1. KB-L30 cells show resistant to microtubule de-stabilizers and hyper-sensitive to microtubule stabilizer. KB and KB-L30 cells
were treated with various concentrations of BPR0L075 (A), colchicine (B), vincristine (C) and paclitaxel (D) for 3 days and cell viability was measured by
MTT cell viability assay.
doi:10.1371/journal.pone.0012564.g001
Table 1. Characterization of KB and KB-L30 cells.
IC50 conc. (nM)
Anti-mitotic
effect KB KB-L30 Differences
BPR0L075 de-stabilizing 7.263.3 42.467.4 6-fold q
Vincristine de-stabilizing 2.761.1 19.566.4 7-fold q
Colchicine de-stabilizing 9.861.5 64.0623.8 7-fold q
Paclitaxel stabilizing 10.061.1 1.660.6 5-fold Q
Doubling
time
26 hours 30 hours
Cells were treated with various drugs for 3 days and cell viability was analyzed
by MTT cell viability assay.
doi:10.1371/journal.pone.0012564.t001
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KB-L30 cells show drug-resistance to microtubule de-
stabilizers and hyper-sensitivity to microtubule stabilizer
A KB-derived BPR0L075-resistant cancer cell line, KB-L30,
was generated in our laboratory. In brief, KB-L30 was a
monoclonal cell line selected for resistance by continual exposure
of the parental cancer cell line, KB, to increasing concentrations of
the microtubule de-stabilizing compound, BPR0L075. KB-L30
cells are cultured in the medium with 30 nM of BPR0L075 to
maintain its drug resistant characteristic. This specific drug-
resistant cancer cell line is 6-fold more resistant to BPR0L075 as
compared to its parental cells (Table 1) (Figure 1A). In addition,
KB-L30 cells exhibit cross-resistance with another microtubule de-
stabilizing agents, colchicine (7-fold resistant) and vincristine (7-
fold resistant) (Table 1) (Figure 1B and C). Surprisingly, this drug-
resistant cancer cell line is 5-fold more sensitive to the microtubule
stabilizing agent paclitaxel as compare to KB cells (Table 1)
(Figure 1D).
Multiple-drug resistant protein (MDR) is not present in
KB-L30 cells
Previous study demonstrated that the microtubule de-stabilizing
compound BPR0L075 was equally effective in both MDR/MRP
negative and positive cancer cells [14], indirectly suggesting that the
BPR0L075-resistance KB-L30 cells exhibit drug resistance proper-
ties through MDR/MRP-independent mechanism. To further
support the above findings, RT-PCR was performed to determine
whether KB-L30 cells over-expressed MDR-1. RT-PCR analysis
revealed that neither KB nor KB-L30 cells express MDR-1
(Figure 2A). In contrast, MDR-1 was expressed in the vincristine-
resistant cancer cell line, KB-VIN10 (positive control) (Figure 2A).
Furthermore, results from the quantitative real-time PCR revealed
that another important drug efflux pump, MPR-1, was not over-
expressed in KB-L30 cells as compared to its parental KB cells
(Figure 2B). In contrast, MRP-1 was over-expressed in the positive
control cell line, KB-20a (Figure 2B). Taken together, these results
suggested that KB-L30 cells induced resistance to microtubule de-
stabilizers through MDR-independent mechanisms.
Figure 2. KB-L30 cells exhibit MDR/MRP-independent drug-resistant properties. The expression of MDR-1 in KB, KB-L30 and KB-VIN10 cells
was analyzed by RT-PCR (A). The expression of MRP-1 in KB, KB-L30 and KB-20a cells was analyzed by real-time PCR (B). GAPDH was used as an
internal control in both RT-PCR and real time PCR analyzes.
doi:10.1371/journal.pone.0012564.g002
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Since KB-L30 cells induced BPR0L075 and cochicine-resis-
tance through MDR/ MRP-independent mechanism, other drug-
resistance mechanisms has been investigated. It has been widely
demonstrated that alterations of the expression of b-tubulin
isotypes at the mRNA level are related to the induction mitotic
drug-resistance in cancer cells [15,16]. Here, expression of b-
tubulin isotypes in KB and KB-L30 cells was analyzed by RT-
PCR. At the mRNA level, the expression of class II and III b-
tubulin isotypes was reduced in KB-L30 cells as compared to the
microtubule de-stabilizers sensitive KB cells (Figure 3A). The
amount of class II and III b-tubulin isotypes expressed in KB-L30
cells was reduced by 35% and 40% as compared to its parental
cells. In contrast, there was no significant difference in the
expression of class I, IVa and IVb b-tubulin isotypes between the
two cell lines (Figure 3A).
KB-L30 cells exhibit multiple mutations in exon four of
the bI-tubulin gene
The contribution of b-tubulin point mutations in inducing drug
resistance to various anti-mitotic compounds was also described
previously [7,8,17]. Since class I b-tubulin represents ,90% of the
total intracellular pool in cells, the gene sequence of bI-tubulin of
KB-L30 cells was analyzed. First, RT-PCR was performed to
determine if any large scale sequence insertion or deletion were
present in exon 1, 2, 3 and 4 of the bI-tubulin gene of KB-L30
cells. Results of RT-PCR and gel electrophoresis revealed no
significant differences in the molecular size (length) of any of the
exons of bI-tubulin gene between KB-L30 and KB cells
(Figure 3B). This result indicated that large scale sequence
insertion or deletion was not present in the bI-tubulin gene of
KB-L30 cells. We further determined the presence of single point
mutation in KB-L30 cells by performing Single-strand Conforma-
tion Polymorphism (SSCP) analysis. SSCP is the electrophoretic
separation of single-stranded nucleic acids based on subtle
differences in sequence (often a single base pair), resulting in a
different secondary structure and a measurable difference in
mobility through a gel. Here, results of SSCP analysis of the bI-
tubulin genomic DNA showed no mobility band shift of exon 1, 2
and 3 of KB-L30, as compared to that of KB cells (Figure 3C).
Surprisingly, SSCP analysis revealed a pattern shift in exon 4 of
bI-tubulin in KB-L30 cells.
DNA sequencing was performed to re-confirm the above
results. Consistent with the results of both RT-PCR and SSCP
analysis, DNA sequencing of the bI-tubulin of KB-L30 cells
revealed no mutation present in its exon 1, 2 and 3 regions (data
not shown). Interestingly, DNA sequencing revealed multiple
mutations present in exon 4 of bI-tubulin of KB-L30 cells. The
sequencing data are the results of a minimum of two experiments.
Six point mutations were found at nucleotide 947 from T to A
(sense), 1114 from A to T, 1145 from C to T, 1213 from G to A,
1294 from G to A and 1310 from G to T (Figure 4A). These
mutations correspond to amino-acid mutations V316D, T372S,
S382L, E405K, E432K and G437K (Figure 4B).
Immunofluorescence staining was performed to determine
whether the mutated bI-tubulin gene did translate into proteins that
were subsequently incorporated into the microtubule networks in
KB-L30 cells. KB-L30 cells were stained with anti-bI-tubulin
antibody and the FITC-conjugated secondary antibody. Results of
the immunofluorescent microscopy revealed that the mutated bI-
tubulin protein was present as part of the microtubule networks
(Figure 4C). To demonstrate that tubulin mutations were indeed
responsible for causing the BPR0L075-resistant phenotype, gene
transfection and over-expression of the bI-tubulin mutant that
contains the above mutations was performed in KB cells. MTT cell
viability assay revealed that KB cells transfected with the mutated bI-
tubulin showed increased resistance to BPR0L075 (IC50 11 nM) as
compared to the cells transfected with the control empty plasmid
(IC50 7 nM) and wild-type bI-tubulin (IC50 7n M )( F i g u r e4 D ) .T h u s ,
the expression of the mutated bI-tubulin did play a role in drug
sensitivity to BPR0L075 in KB cells.
Computer modeling studies for bI-tubulin mutations in
BPR0L075 resistance
Tubulin mutations can be associated with either altered drug-
binding site or changes in microtubule stability. Here, computational
modeling was employed to give structural insights. The three-
dimensional tubulin structure (PDB code: 1SA0) was used [18] and
the program Discovery Studio 2.1 (Accelrys, Inc) was applied to build
model by mutating residues and performing energy minimization. In
this model, the V318D residue (corresponding to V316D in KB-L30)
is located in the colchicine-binding site on bI-tubulin (Figure 5A).
Val318 (wild type) formed hydrophobic interactions with colchicine.
However, the mutated residue (V mutated to D) shifts away from
colchicine to form a hydrogen bond with residue R320, resulting in
the loss of hydrophobic interaction with colchicine (Figure 5A) in the
modeling study. This result indicates that V318D may weaken the
binding affinity of colchicine to b-tubulin. On the other hand,
mutations of residue 392 (located in Helix 11) and residue 382
(located in the loop near Helix 11) change the conformation of Helix
11, which might increase the longitudinal interactions and conse-
quently alter the stability of microtubules (Figure 5B) [19]. E415K
(corresponding to E405K in KB-L30)i sl o c a t e di nt h eH 1 1 - H 1 2
region near the dimer interface that is involved in longitudinal
contacts. Residue 415, mutated from Glu to Lys, breaks the
hydrogen-bond interactions with residue K402 and consequently
leads to the movement of K402 closer to the a-tubulin. The shift of
the K402 residue (Figure 5C) leads to close contacts with
residues?V260, Y262 and W346 in the a-tubulin, increasing the
interactions between b-tubulin and a-tubulin. Helix 11 is located in
the interface of a-tubulin and b-tubulin dimer. In conclusion, the
computational modeling study indicates that tubulin mutations in
KB-L30 cells may increase microtubule assembly and stability.
KB-L30 cells exhibit increased microtubule assembly and
reduced microtubule dynamics
To determine whether the stability and dynamics of microtu-
bule in KB-L30 cells were affected by mutations in the bI-tubulin
as predicated by computational analysis, Western blot analysis was
performed. Here, Western blot analysis revealed that the amount
both a- and b-tubulin pellets present in KB-L30 cells were
increased when compared to its parental KB cells (Figure 6A). In
contrast, the soluble form of b-tubulin present in KB-L30 cells was
decreased compared to that of KB cells (Figure 6A). Immunoflu-
orescence staining was also used to further support the above
Figure 3. KB-L30 cells exhibit alterations in the expression of b-tubulin isotypes and mutations in the class III b-tubulin gene. The
expression of different b-tubulin isotypes in KB and KB-L30 cells was analyzed by RT-PCR. GAPDH was used as an internal control (A). RT-PCR and
nested-PCR analyzes of exons 1, 2, 3 and 4 in the class III b-tubulin gene of KB and KB-L30 cells. First lane, KB cells and second lane, KB-L30 cells (B).
PCR-SSCP analyzes of exons 1, 2, 3 and 4 in the class III b-tubulin gene of KB and KB-L30 cells. First lane, KB cells and second lane, KB-L30 cells (C).
doi:10.1371/journal.pone.0012564.g003
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anti-b-tubulin antibody and cells were viewed under the
microscope. KB-L30 cells seem to have higher microtubule
content as compared to KB cells (Figure 6B). In addition, the
use of microtubule de-stabilizer, BPR0L075, was able to reduce
the microtubule content in KB-L30 cells (Figure 6B). Taken
together, our results suggested that KB-L30 cells exhibited
increased microtubule assembly.
Microtubule dynamic instability is characterized by abrupt
stochastic transitions between phases of extension and shortening.
At the molecular level, increased a-tubulin acetylation is
considered to be a marker of the reduced dynamic of microtubule.
Here, Western blot analysis revealed that the amount of acetylated
a-tubulin was decreased in BPR0L075-incubated KB cells in a
concentration-dependent manner (Figure 6C). In contrast, the
amount of acetylated a-tubulin was increased in paclitaxel-
incubated cells (Figure 6C). Microtubule de-stabilizer was found
functioning in inducing the microtubule dynamic instability and
microtubule stabilizer was found functioning in reducing the
microtubule dynamic instability [20,21]. Thus, the amount of
acetylated a-tubulin present in cells might be related to the
sensitivity of cells to various anti-mitotic compounds. To
determine whether KB-L30 cells exhibited reduced microtubule
dynamics, Western blot analysis was used to determine the level of
a-tubulin acetylation present in the drug-resistant cells. Here,
Western blot analysis revealed that the amount of acetylated a-
tubulin was increased in KB-L30 cells, as compared to KB cells
(Figure 6D). Consistent with the prediction from the computa-
tional model, our results revealed that KB-L30 cells exhibited both
enhanced microtubule stabilization and reduced microtubule
dynamics. Furthermore, our data indicate that the alteration of
microtubule stability and dynamic in KB-L30 cells may be caused
by the presence of mutated bI-tubulin, resulting in the resistance to
microtubule de-stabilizers and hyper-sensitivity to microtubule
stabilizers.
Discussion
Anti-mitotic compounds have been shown successful in treating
various cancers. However, development of drug-resistance cells
limits their efficacies in clinical situations. Therefore, it is
important to determine possible drug resistance mechanism
related to the application of anti-mitotic cancer therapy. Positive
correlation between the expression of multi-drug resistance
proteins MDR-1, MRP-1 and the induction of drug resistance to
anti-mitotic compounds in cancers has been widely reported
previously [4,5]. However, drug resistance to anti-mitotic
compounds in cancer cells is thought to be multi-factorial. Here,
we demonstrated that the BPR0L075-resistant KB-L30 cells do
not express MDR-1 and MRP-1. Importantly, the current study
indentifies novel sites of mutation in the exon 4 of bI-tubulin that
are able to induce both drug resistance to microtubule de-
stabilizers and hyper-sensitivity to microtubule-stabilizers through
both alterations in the drug-binding site and microtubule stability.
The BPR0L075-resistant KB-L30 cells used in this study seems
to acquire its drug-resistant properties through MDR/MRP-
independent mechanisms. Firstly, KB-L30 cells did not express
two of the most common drug efflux pumps, MDR-1 and MRP-1.
In addition, unlike traditional microtubule inhibitors such as
vincristine and paclitaxel, BPR0L075 is effective in suppressing
cell growth of both MDR/MRP-positive and –negative tumor cell
lines [14]. In vivo, BPR0L075 showed potent activity against the
growth of xenograft tumors of the gastric carcinoma MKN-45,
human cervical carcinoma KB, and KB-derived P-gp170/MDR -
overexpressing KB-VIN10 cells in nude mice [14]. However,
BPR0L075 was ineffective in inducing the death of KB-L30 cells in
this study. Therefore, our study indicated that MDR/MRP did
not play an important role in the resistance to microtubule de-
stabilizers such as BPR0L075, colchicine and vincristine in KB-
L30 cells.
Since MDR and MRP did not play an important role in the
induction of drug resistance in KB-L30 cells, other drug resistance
mechanisms must be present in the cells. Tubulin-binding com-
pounds such as vincristine, colchicine and paclitaxel, inhibit the
progress of cell mitosis through the inhibition of the dynamic
formation of mitotic spindle during G2/M phase. Therefore,
mutations in the drug target, tubulin, may interfere with the
effectiveness of anti-mitotic compounds. In fact, mutations in both
a-a n db-tubulin in Chinese hamster ovary cells have been shown to
result in resistance to colchicine and vinblastine [8]. Furthermore,
mutations in the b-tubulin in ovarian cancer cells have been shown to
result in resistance to epothilone and taxanes [22]. In this study, six
novel mutation sites were found present in the bI-tubulin gene of KB-
L30 cells. These mutations correspond to amino-acid mutations
V316D, T372S, S382L, E405K, E432K and G437K. These
mutation sites are presented in the exon four regions instead of exon
one, two and three that have been previously identified [7]. This is
particularly important as mutations in exon four in causing anti-
mitotic drug resistance are lessdemonstrated when compared to exon
1, 2 and 3. In this study, over-expression of the mutant tubulins
(contained multiple mutated-sites) in KB cells reduced the drug
sensitivity to the microtubule de-stabilizing compound BPR0L075 as
compared to cells transfected with empty vector or wildtype tubulin.
The small differences between cells transfected with mutated-tubulin
and wildtype tubulin were probably due to the large amount of the
endogenously expressed wildtype tubulin present in the transfected
KB cells. Transfection of constructs that contain b-tubulin with
different single site mutation in KB cells was also performed to
determine whether a specific sing l es i t em u t a t i o ni nt h eg e n ew a s
indeed enough to cause drug resistance to BPR0L075 (data not
shown). However, results of our study revealed no significant
difference in drug sensitivity between cells transfected with the
mutant (single site mutation) and wildtype bI-tubulin (data not
shown). This result can possibly be explained by the followings: 1) the
mutation sites were not directly located on the specific drug binding
sites and 2) the three dimensional structure of bI-tubulin was not
significantly altered by any single site mutation that was revealed in
this study. Instead, all six mutations present on exon 4 might together
contribute to the alteration of the bI-tubulin’s three dimensional
structures, resulting in the changes of drug sensitivity in KB-L30 cells.
With the use of computational modeling, the mutant regions in
the computational model which we predicted were analyzed to
compare with the increase or decrease of the interactions before
and after mutations. In our model, the locations of bI-tubulin
mutations were identified and the resulting conformation changes
Figure 4. Mutations in exon 4 of bIII-tubulin interfere with the sensitivity of BPR0L075 in KB-L30 cells. DNA sequencing of the bI-tubulin
genomic DNA reveals six point mutations present in exon 4 (A). Translated amino-acid sequence of the mutated exon 4 of the bI-tubulin gene (B). The
expression of the mutated bI-tubulin protein and its incorporation in the microtubule networks were revealed by immuno-fluorescent microscopy.
Cells were probed with anti-bI-tubulin antibody (C). Transfection of the mutated bI-tubulin gene into KB cells reduced the drug sensitivity to
BPR0L075 in vitro (D).
doi:10.1371/journal.pone.0012564.g004
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microtubule assembly and stability. In agreement with the
computational model, increased tubulin polymer levels were
observed in the BPR0L075-resistant KB-L30 cells as compared
to its drug-sensitive parental cells (Figure 6A and 6B). In addition,
the level of acetylated a-tubulin was also increased in KB-L30 cells
(Figure 6D), indicating that reduced microtubule dynamic
instability was present in this specific cell line. A role for altered
microtubule polymer levels in vincristine resistance of acute
lymphoblastic leukemia has been demonstrated in vivo previously
[23]. In addition, a vincristine-resistant xenograft with high levels
of polymerized tubulin was shown relatively sensitive to the
microtubule-polymerizing drug paclitaxel [23]. Furthermore, a
study also reported that the dynamic instability of microtubules of
paclitaxel-resistant A549-T12 cancer cells was significantly
increased as compared to its parental cells [24]. Thus, enhanced
microtubule polymerization and reduced dynamic instability
caused by tubulin mutations may represent a survival mechanism
against microtubule de-stabilizing compounds. On the other hand,
the enhanced microtubule polymerization and reduced dynamic
instability may improve the effectiveness of microtubule stabilizing
compounds such as paclitaxel. In fact, our published study
demonstrated that down-regulation of survivin (IAPs) induced
microtubule de-polymerization, resulting in increased drug
sensitivity of KB cells to colchicine and BPR0L075 [13]. In
addition, the same treatment partially restored sensitivity of KB-
L30 cells to BPR0L075 through the process of microtubule de-
polymerization [13]. However, down-regulation of survivin did
not affect the activity of caspases [13]. Taken together, these
results indicated that the balance between polymerized and non-
polymerized tubulin may be an important determinant of response
to anti-mitotic based chemotherapy.
It is also worth noting that the down-regulation of bII- and bIII-
tubulin isotypes was observed in KB-L30 cells. Literature revealed
that the over-expression of bIII-tubulin induced paclitaxel- and
docetaxel-resistance in cancer cells [7,10,16]. High level of bIII-
tubulin expression was also shown to be associated with the resistance
to paclitaxel and decreased survival in patients with carcinoma [25].
Interestingly, a recent study from Tseng et al. has provided a possible
explanation for this phenomenon. Mathematical and computational
models of their study indicate that microtubule de-stabilizing agents,
colchincine and its derivatives, bind strongest to the bIII-tubulin as
compare to other b-tubulin isotypes [26]. Thus, changes in the
expression of bIII-tubulin can alter the sensitivity to colchicine
derivatives that inhibit the polymerization of microtubules. There-
fore, down-regulation of the bIII-tubulin may also contribute to the
enhanced sensitivity to paclitaxel and the reduced sensitivity to
colchicine/BPR0L075 in KB-L30 cells.
In conclusion, we showed that novel mutations in exon 4 of the
bI-tubulin induced resistance to microtubule de-stabilizers and
hyper-sensitivity to microtubule stabilizer through alteration in the
microtubule assembly and dynamics in cancer cells. This report
further indicates that cancer cells may alter the stability and
dynamics of microtubule networks through multiple mechanisms
such as tubulin mutations and differential isotype expressions
simultaneously, resulting in the resistant to anti-mitotic cancer
therapy. The results of this study provide molecular information in
drug selection for patients with specific tubulin mutations and also
have important implications for the development of future anti-
mitotic compounds that are able to target drug-resistant cancer
cells. Nevertheless, further investigations are needed to determine
whether these specific bI-tubulin mutations can be found in clinical
samples (post-treatment) and its correlation to drug resistance.
Figure 5. The computational modeling study indicates that
tubulin mutations in KB-L30 cells may increase microtubule
assembly and stability (A, B and C).
doi:10.1371/journal.pone.0012564.g005
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Cell lines, antibodies and reagents
Human oral carcinoma cells (KB) were purchased from the
American Type Culture Collection (ATCC, Manassas, VA). This
specific cancer cell line was also described as a HeLa contaminant
by ATCC. KB and KB-derived KB-L30 cells were cultured in
RPMI 1640 medium (Gibco, Grand Island, NY), supplemented
with 5% fetal bovine serum, penicillin (100 U/mL), streptomycin
(100 mg/mL) and L-glutamine (0.29 mg/mL), at 37uC. The
antibodies used in this study included: a mouse anti-atubulin
antibody (Upstate Cell signaling, Lake Placid, NY), a mouse anti-
btubulin antibody (BD PharMingen, Franklin Lakes, NJ) and a
mouse anti-actin antibody (Santa Cruz Biotechnology, Santa
Cruz, CA).
Establishment of the KB-derived BPR0L075-resistant cell
line
Human oral carcinoma cells (KB) were cultured in RPMI 1640
medium as previously described. BPR0L075-resistant cells were
established from KB cells by exposure to increasing concentrations
of BPR0L075. Briefly, KB cells were initially incubated in
completed medium containing 5 nM of BPR0L075 that yielded
40% cell survival for a period of 3,4 weeks, and the cells that
Figure 6. KB-L30 cells exhibit increased microtubule assembly and reduced microtubule dynamics. The amount of soluble and insoluble
a- and b-tubulin in KB and KB-L30 cells was analyzed by Western blotting. Actin was used as a loading control (A). The integrity of microtubule
networks in KB and KB-L30 cells was showed by immuno-fluorescent microscopy. Cells were probed with anti-b-tubulin antibody (B). Microtubule
dynamics in cells were analyzed by western blot analysis. Acetylated-a-tubulin was used as an indirect indicator of microtubule dynamics and the
amount of acetylated-a-tubulin was analyzed in BPR0L075 and paciltaxel-treated KB cells by Western blotting. Alpha-tubulin (total form) was used as
the loading control (C). The amount of the endogenously acetylated-a-tubulin in KB and KB-L30 cells was analyzed by Western blotting. Alpha-tubulin
(total form) was used as the loading control (D).
doi:10.1371/journal.pone.0012564.g006
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containing increasing concentrations of the drug (at 20%
increment each time). A mixed population of cells that grew
exponentially in the present of 15 nM of BPR0L075 were
obtained and further cultured in complete medium containing
increasing concentrations of the drug to 20 nM of BPR0L075.
Then, cells that grew exponentially in the present of 20 nM of
BPR0L075 were obtained and subsequently cultured in complete
medium containing increasing concentrations of the drug to
30 nM of BPR0L075. Cells that grew exponentially in the
presence of 30 nM of BPR0L075 were obtained and subcloned
by dilution plating in 48-well plates. Six individual clones were
isolated. For maintenance, these subclones were cultured under
conditions similar to those used for KB, except for the addition of
BPR0L075 (30 nM). Since all of these subclones exhibited similar
drug sensitivity to BPR0L075 and other microtubule de-stabilizers,
only one subclone, KB-L30, was selected and further investigated
in this study.
RT-PCR
Total RNA was extracted with using TRIzol reagent (Invitro-
gen, Carlsbad, CA) and complementary DNA was synthesized
from RNA with the SuperScriptTM First-Strand Synthesis
System (Invitrogen, Carlsbad, CA). Expression levels of bI, bII,
bIII, bIVa and bIVb-tubulin transcript were determined by
reverse transcriptase (RT)-polymerase chain reaction (PCR).
Specific primers with following sequences were used: bI, bII,
bIII, bIVa and bIVb-tubulin common forward, 59 CAACAG-
CACGGCCATCCAGG; bI-tubulin reverse, 59 AAGGGGG-
CAGT TGAGTAAGACGG; bII-tubulin reverse, 59 GTA-
GAAAGACCATGCTTGGG; bIII-tubulin reverse, 59 CTTGG-
GGCC CTGGGCCTCCGA; bIVa-tubulin reverse, 59 AAG-
TAGCCAGAGGTAAAGCGA and bIVb-tubulin reverse, 59
CTTTCCCCAGTGACTGAAGG. To amplify different exons
of bIII-tubulin, polymerase chain reaction was performed with
target-specific primers that have been previously published [27]
(Table 2) (Figure S1). PCR cycling conditions were as follows: an
initial denaturing step at 95uC for 10 min, 40 cycles at 95uCf o r
30 sec, 50uC–58uC for 30 sec, 72uC for 30 sec, followed by a
final period of extension at 72uC for 5 min. For amplification of
the whole region of exon 4, the extension time was extended by
2m i n .
Single-stranded conformation polymorphism (SSCP)
analysis
Genomic DNA was extracted from KB and KB-L30 cells. SSCP
analysis was performed using 5% nondenaturing polyacrylamide
gels (acrylamide/N,N-bisacrylamide 99:1) containing 10% glycer-
ol. After electrophoresis for 4.5 h at 850 V, the gels were stained
with SYBR Green II (TaKaRa, Otsu, Japan) and scanned with a
fluorescence image analyzer (Alpha Innotech, San Leandro, CA).
SDS-PAGE and Western Blot Analysis
Cells were lysed with ice-cold lysis buffer (10 mM Tris, 1 mM
EDTA, 1 mM DTT, 60 mM KCl, 0.5% v/v NP-40 and protease
inhibitors). Total cell lysates, fractions of supernatant or pellet
were resolved on 10% and 12% polyacrylamide SDS gels under
reducing conditions. The resolved proteins were electrophoreti-
cally transferred to PVDF membranes (Amersham Life Science,
Amersham, U.K.) for Western blot analysis. The membranes were
blocked with 5% non-fat milk powder at room temperature for
two hours, washed twice with PBST (1% Tween) and then
incubated with primary antibody for 90 minutes at room
temperature. The membranes were washed twice with PBST
then subsequently incubated with a horseradish peroxidase-
conjugated secondary antibody (dilution at 1:10000, Santa Cruz
Biotechnology, Santa Cruz, CA). Immunoreactivity was detected
by Enhanced Chemiluminescence (Amersham International,
Buckingham, U.K.) and autoradiography.
Computational modeling
We employed the program Discovery Studio 2.1 (Accelrys, Inc)
to build the computational models of tubulin mutants. The three-
dimensional structure of wild-type tubulin (PDB code: 1SA0) was
used as a template to perform energy minimization. The force
fields of conformations were further check with CHARMm, and
the parameters used were set as default values.
Supporting Information
Figure S1 Schematic diagram showing the process of PCR with
different PCR primers.
Found at: doi:10.1371/journal.pone.0012564.s001 (1.65 MB TIF)
Author Contributions
Conceived and designed the experiments: CHAC JYC. Performed the
experiments: CHAC CYC. Analyzed the data: CHAC SYW TRL JSW.
Contributed reagents/materials/analysis tools: SYW JSW HPH JYC.
Wrote the paper: CHAC SYW.
References
1. Valiron O, Caudron N, Job D (2001) Microtubule dynamics. Cell Mol Life Sci
58: 2069–2084.
2. Arrieta O, Rodriguez-Diaz JL, Rosas-Camargo V, Morales-Espinosa D, Ponce
de Leon S, et al. (2006) Colchicine delays the development of hepatocellular
Table 2. Different primers used in the PCR and SSCP analysis.
Primer Sequence
Exon 1 Forward AACCTTCCAGCCTGCGAC
Reverse ACTTACCTGGATTTTTCCTTG
Exon 2 Forward TAGTTGGGGACATAGTTGGC
Reverse TAAGGCGTGCCCAGAAATGG
Exon 3 Forward AATGACAAGTCTCTGATCCC
Reverse TCCAATACAACAATCATCTCC
Exon 4 Forward TGTATTGGAGTGCTAATACAG
Reverse CTCCCTTGAAGCTGAGATGG
Exon 4a Forward CATGTATCTTCCATACCCTG
Reverse CTGAAGGTATTCATGATGCG
Exon 4b Forward GAATGGGCACTCTCCTTATC
Reverse GGACCATGTTGACTGCCAAC
Exon 4c Forward ATGAGTGGTGTCACCACCTG
Reverse GACTGCCATCTTGAGGCCAC
Exon 4d Forward CCCAACAATGTCAAGACAGC
Reverse CAAGATAGAGGCAGCAAACAC
All primer sequences are listed in the direction of 59 to 39.
doi:10.1371/journal.pone.0012564.t002
Tubulin and Drug Resistance
PLoS ONE | www.plosone.org 10 September 2010 | Volume 5 | Issue 9 | e12564carcinoma in patients with hepatitis virus-related liver cirrhosis. Cancer 107:
1852–1858.
3. Tanaka Y, Fujiwara K, Tanaka H, Maehata K, Kohno I (2004) Paclitaxel
inhibits expression of heat shock protein 27 in ovarian and uterine cancer cells.
Int J Gynecol Cancer 14: 616–620.
4. Kohno K, Kikuchi J, Sato S, Takano H, Saburi Y, et al. (1988) Vincristine-
resistant human cancer KB cell line and increased expression of multidrug-
resistance gene. Jpn J Cancer Res 79: 1238–1246.
5. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, et al. (1998) Levels
of multidrug resistance (MDR1) P-glycoprotein expression by human breast
cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer
Res 4: 389–398.
6. Kim D, Kim K-O, Shin M, Ha J, Seo S, et al. (2009) siRNA-based targeting of
antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing
chondrosarcoma cells. Molecular Cancer 8: 28.
7. Huzil JT, Chen K, Kurgan L, Tuszynski JA (2007) The Roles of beta-Tubulin
Mutations and Isotype Expression in Acquired Drug Resistance. Cancer Inform
3: 159–181.
8. Hari M, Wang Y, Veeraraghavan S, Cabral F (2003) Mutations in alpha- and
beta-tubulin that stabilize microtubules and confer resistance to colcemid and
vinblastine. Mol Cancer Ther 2: 597–605.
9. He L, Yang CP, Horwitz SB (2001) Mutations in beta-tubulin map to domains
involved in regulation of microtubule stability in epothilone-resistant cell lines.
Mol Cancer Ther 1: 3–10.
10. Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, et al. (2003) Analysis of
tubulin isotypes and mutations from taxol-resistant cells by combined
isoelectrofocusing and mass spectrometry. Biochemistry 42: 5349–5357.
11. Kamath K, Wilson L, Cabral F, Jordan MA (2005) BetaIII-tubulin induces
paclitaxel resistance in association with reduced effects on microtubule dynamic
instability. J Biol Chem 280: 12902–12907.
12. Seve P, Reiman T, Dumontet C (2010) The role of betaIII tubulin in predicting
chemoresistance in non-small cell lung cancer. Lung Cancer 67: 136–143.
13. Cheung CH, Chen HH, Kuo CC, Chang CY, Coumar MS, et al. (2009)
Survivin counteracts the therapeutic effect of microtubule de-stabilizers by
stabilizing tubulin polymers. Mol Cancer 8: 43.
14. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, et al. (2004) BPR0L075, a
novel synthetic indole compound with antimitotic activity in human cancer cells,
exerts effective antitumoral activity in vivo. Cancer Res 64: 4621–4628.
15. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, et al. (2007)
Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
Int J Cancer 120: 2078–2085.
16. Shalli K, Brown I, Heys SD, Schofield AC (2005) Alterations of beta-tubulin
isotypes in breast cancer cells resistant to docetaxel. FASEB J 19: 1299–1301.
17. Wang Y, O’Brate A, Zhou W, Giannakakou P (2005) Resistance to microtubule-
stabilizing drugs involves two events: beta-tubulin mutation in one allele followed
by loss of the second allele. Cell Cycle 4: 1847–1853.
18. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, et al. (2004) Insight into
tubulin regulation from a complex with colchicine and a stathmin-like domain.
Nature 428: 198–202.
19. Nogales E, Whittaker M, Milligan RA, Downing KH (1999) High-resolution
model of the microtubule. Cell 96: 79–88.
20. Piperno G, LeDizet M, Chang XJ (1987) Microtubules containing acetylated
alpha-tubulin in mammalian cells in culture. J Cell Biol 104: 289–302.
21. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, et al. (2002) In
vivo destabilization of dynamic microtubules by HDAC6-mediated deacetyla-
tion. EMBO J 21: 6820–6831.
22. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, et al. (2000)
A common pharmacophore for epothilone and taxanes: molecular basis for drug
resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad
Sci U S A 97: 2904–2909.
23. Ong V, Liem NL, Schmid MA, Verrills NM, Papa RA, et al. (2008) A role for
altered microtubule polymer levels in vincristine resistance of childhood acute
lymphoblastic leukemia xenografts. J Pharmacol Exp Ther 324: 434–442.
24. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, et al. (2001)
Resistance to Taxol in lung cancer cells associated with increased microtubule
dynamics. Proc Natl Acad Sci U S A 98: 11737–11742.
25. Seve P, Reiman T, Lai R, Hanson J, Santos C, et al. (2007) Class III beta-
tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary
site. Cancer Chemother Pharmacol 60: 27–34.
26. Tseng C-Y, Mane J, Winter P, Johnson L, Huzil T, et al. (2010) Quantitative
analysis of the effect of tubulin isotype expression on sensitivity of cancer cell
lines to a set of novel colchicine derivatives. Molecular Cancer 9: 131.
27. Urano N, Fujiwara Y, Hasegawa S, Miyoshi Y, Noguchi S, et al. (2003) Absence
of beta-tubulin gene mutation in gastric carcinoma. Gastric Cancer 6: 108–112.
Tubulin and Drug Resistance
PLoS ONE | www.plosone.org 11 September 2010 | Volume 5 | Issue 9 | e12564